Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction

Clinical Drug Investigation
Mikie YamatoMitsutaka Takada

Abstract

This retrospective cohort study was performed to examine the association between serum amiodarone (AMD) and N-desethylamiodarone (DEA) concentrations and the development of thyroid dysfunction. Patients treated with AMD from January 2012 to April 2016 were identified from the computerized hospital information system database at the National Cerebral and Cardiovascular Center. Only patients whose serum AMD and DEA concentrations had been determined at least once were included in the study. A total of 377 patients were enrolled. Consequently, 54 (14.3%) and 60 (15.9%) patients who developed AMD-induced thyrotoxicosis and hypothyroidism were included. The mean DEA/AMD ratio during the pre-index period in the thyrotoxicosis group (0.86 ± 0.24) was significantly higher than in the hypothyroidism (0.68 ± 0.27) and euthyroidism (0.78 ± 0.30; p < 0.0001) groups. In addition, the mean DEA/AMD ratio during the post-index period in the thyrotoxicosis group (1.05 ± 0.40) was significantly higher than in the hypothyroidism (0.81 ± 0.24) and euthyroidism (0.88 ± 0.22; p < 0.0001) groups. A persistently higher DEA/AMD ratio was observed throughout the study period in the thyrotoxicosis group. In addition, good correlations between the DEA/AMD...Continue Reading

References

Dec 15, 1989·Biochemical Pharmacology·S A BeddowsS S Nussey
Jan 1, 1987·Hormone Research·E MartinoA Pinchera
Feb 1, 1987·Clinical Endocrinology·E MartinoA Pinchera
Jul 1, 1984·Annals of Internal Medicine·E MartinoC Haffajee
Oct 1, 1983·American Heart Journal·D W HoltG C Storey
Sep 1, 1997·Journal of the American College of Cardiology·V R VorperianC T January
Jun 29, 2000·Clinical Pharmacology and Therapeutics·P T PollakS L Shafer
Nov 25, 2003·QJM : Monthly Journal of the Association of Physicians·J Sidhu, D Jenkins
Jul 2, 2005·The American Journal of Medicine·Shehzad Basaria, David S Cooper
Oct 6, 2005·Biological & Pharmaceutical Bulletin·Asami KashimaKazuyuki Ueno
Dec 27, 2005·Current Drug Targets. Immune, Endocrine and Metabolic Disorders·N J Sarlis, L Gourgiotis
Mar 18, 2006·Arquivos brasileiros de endocrinologia e metabologia·Beatriz D SchaanMiguel Gus
Feb 23, 2010·Biochemical and Biophysical Research Communications·Monica A IstrateOliver Burk
Nov 13, 2010·Biochemical Pharmacology·Anja ZahnoStephan Krähenbühl
Jan 11, 2011·Basic & Clinical Pharmacology & Toxicology·Nobumitsu HaniokaShizuo Narimatsu
May 4, 2011·Clinical Endocrinology·Sheba AhmedThera P Links
Apr 17, 2012·Toxicology and Applied Pharmacology·Young Joo ParkDavid D Moore
Mar 8, 2014·Heart and Vessels·Filippo BenassiMarco Meli
Jan 14, 2017·European Journal of Clinical Pharmacology·Mikie YamatoMitsutaka Takada

❮ Previous
Next ❯

Citations

Aug 11, 2019·Journal of Clinical Pharmacy and Therapeutics·Sayoko KinoshitaMitsutaka Takada
May 16, 2020·Annales d'endocrinologie·Louis SchubertLionel Groussin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.